Filing Analysis
Metagenomi Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026, and provided additional business updates via a press release.
📋 Key Facts
- Report date: August 10, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'emerging growth company'
Metagenomi Therapeutics reported the resignation of board member Brian C. Thomas, Ph.D., and the results of its 2026 annual meeting of stockholders. The meeting resulted in the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
🚩 Red Flags
- Multiple 8-K items (5.02 and 5.07) in a single filing, though both are routine administrative matters.
📋 Key Facts
- Brian C. Thomas, Ph.D. resigned from the Board of Directors effective June 9, 2026.
- The Company held its 2026 annual meeting on June 9, 2026, with a quorum of 19,116,207 shares present out of 37,647,057 outstanding.
- Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. were elected as Class II Directors to serve until 2029.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Metagenomi Therapeutics reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The filing also included an updated corporate presentation for May 2026.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026.
- Furnished Exhibit 99.1 (Earnings Press Release) and Exhibit 99.2 (Corporate Presentation).
- The report was signed by CEO Jian Irish on May 11, 2026.
Metagenomi Therapeutics, Inc. (MGX) furnished its financial results for the fiscal year ended December 31, 2025, and provided general business updates. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Announcement date: March 5, 2026
- Reporting period: Fiscal year ended December 31, 2025
- Filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits)
- The company is classified as an emerging growth company
- The report was signed by President and CEO Jian Irish, Ph.D., M.B.A.
Metagenomi, Inc. has officially changed its corporate name to Metagenomi Therapeutics, Inc., effective January 12, 2026. The change was implemented via an amendment to the Certificate of Incorporation and a restatement of the company's bylaws.
📋 Key Facts
- Company name changed from 'Metagenomi, Inc.' to 'Metagenomi Therapeutics, Inc.' effective Jan 12, 2026.
- The change was approved by the Board of Directors pursuant to Delaware law; no stockholder vote was required.
- Ticker symbol remains 'MGX' on the Nasdaq Global Select Market.
- CUSIP number for common stock remains unchanged.
- Amended and Restated Bylaws were filed to reflect the name change.
Metagenomi, Inc. announced its financial results for the quarter ended September 30, 2025, and provided a clinical update regarding positive dose-range finding data for its MGX-001 hemophilia A program.
📋 Key Facts
- Reported quarterly financial results for the period ending September 30, 2025 (Item 2.02).
- Announced positive dose range finding data from the MGX-001 hemophilia A program (Item 7.01).
- Released a new corporate presentation dated November 2025.
Metagenomi entered into a non-exclusive license agreement with Acuitas Therapeutics for LNP technology while simultaneously terminating its development agreement with Affini-T Therapeutics due to Affini-T's insolvency (assignment for the benefit of creditors). The filing represents a strategic pivot, regaining IP rights from a failing partner while securing critical delivery technology.
🚩 Red Flags
- Loss of a licensee/partner due to insolvency (Affini-T Therapeutics making an assignment for the benefit of creditors).
- Termination results in loss of all future payments from the Affini-T agreement.
📋 Key Facts
- Entered into Non-Exclusive License Agreement with Acuitas Therapeutics on September 29, 2025.
- Acuitas license includes LNP technology, formulation processes, and analytical characterization for genome editing constructs.
- License terms include a low seven-figure annual maintenance fee until Phase 1 dosing, milestone payments in the low to mid seven figures, and royalties in the low mid-single digit percentage of net sales.
- Terminated Development, Option and License Agreement with Affini-T Therapeutics on September 30, 2025.
- Termination of Affini-T agreement triggered by Affini-T making an assignment for the benefit of creditors (insolvency).
- Metagenomi regained full control over IP rights previously licensed to Affini-T and the right to operate in previously restricted areas.
Metagenomi, Inc. announced its financial results for the quarter ended June 30, 2025, and provided an updated corporate presentation. The filing serves as a routine disclosure of quarterly earnings and business updates.
📋 Key Facts
- Reported financial results for the second quarter ended June 30, 2025.
- Furnished a new corporate presentation dated August 2025 (Exhibit 99.2).
- The filing includes an earnings press release (Exhibit 99.1).
Metagenomi, Inc. held its 2025 annual meeting of stockholders on June 10, 2025. The company successfully elected a new Class I Director and ratified the appointment of PricewaterhouseCoopers LLP as its independent auditor.
📋 Key Facts
- Annual Meeting held via virtual webcast on June 10, 2025.
- Willard H. Dere, M.D. was elected to the Class I Director position (term until 2028).
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Quorum was established with 18,765,221 shares present out of 37,382,478 outstanding shares.
Metagenomi, Inc. issued an 8-K to announce the presentation of three scientific abstracts at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting held in May 2025.
📋 Key Facts
- The company presented three abstracts at the ASGCT 28th Annual Meeting.
- The meeting took place from May 13 – 17, 2025, in New Orleans, Louisiana.
- Filing includes a press release as Exhibit 99.1.
Metagenomi, Inc. announced its quarterly financial results for the period ending March 31, 2025, and provided a corporate presentation update.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2025.
- Released a new corporate presentation dated May 2025 (Exhibit 99.2).
- The filing includes information intended to satisfy Regulation FD requirements.
Metagenomi, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to facilitate an 'at-the-market' (ATM) offering of common stock. The agreement allows the company to sell up to $75,000,000 in shares at its discretion.
🚩 Red Flags
- Potential dilution for existing shareholders due to the $75M ATM offering.
- ATM offerings are often used by micro-cap/growth companies to bolster cash runway, which can signal upcoming capital needs.
📋 Key Facts
- Entered into Open Market Sale Agreement with Jefferies LLC on March 17, 2025.
- Aggregate offering price of up to $75,000,000 in common stock.
- Sales will be conducted via an 'at-the-market' (ATM) offering mechanism under Rule 415.
- Jefferies LLC will act as sales agent on a best efforts basis.
- The company will pay Jefferies a commission fee of up to 3.0% of gross proceeds.
- The offering is based on a Form S-3 Registration Statement filed on March 17, 2025.
Metagenomi, Inc. filed an 8-K to announce its full-year 2024 financial results and provide a corporate business update via a press release and presentation.
📋 Key Facts
- Announced financial results for the fiscal year ended December 31, 2024.
- Provided an updated corporate presentation (Exhibit 99.2) to communicate business developments.
- The filing includes information furnished under Item 2.02 and Item 7.01.
Metagenomi, Inc. announced the appointment of Eric Bjerkholt to its Board of Directors, effective January 27, 2025. The board is expanding from five to six members, and Mr. Bjerkholt will serve on both the Audit and Compensation Committees.
📋 Key Facts
- Board size increasing from five to six directors.
- Eric Bjerkholt appointed as a Class II director effective January 27, 2025.
- Mr. Bjerkholt will serve on the Audit Committee and Compensation Committee.
- Compensation includes annual retainers and a one-time grant of 42,000 non-statutory stock options vesting over three years (starting February 3, 2025).
- The appointment was made upon recommendation of the Nominating and Corporate Governance Committee.
Metagenomi, Inc. issued an 8-K to announce the presentation of updated preclinical nonhuman primate data for its hemophilia A program at the American Society of Hematology (ASH) 66th Annual Meeting.
📋 Key Facts
- The company presented updated preclinical nonhuman primate data for its hemophilia A program.
- Presentation occurred during an oral presentation at the ASH 66th Annual Meeting and Exposition in San Diego.
- Data was released via press release on December 9, 2024.
Metagenomi, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024, and provided additional business updates.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Filing date: November 13, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and business updates.
- Company is an emerging growth company.
Metagenomi, Inc. announced preclinical data regarding the durability and safety of its hemophilia A gene editing investigational therapy, MGX-001. The filing serves as a formal announcement of scientific progress rather than a material corporate structural change.
📋 Key Facts
- Announcement date: September 3, 2024
- Subject matter: Preclinical study data for MGX-001 (hemophilia A gene editing therapy)
- Focus of data: Potential durability and safety of the investigational therapy
- The filing incorporates a press release as Exhibit 99.1
Metagenomi, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided additional business updates.
📋 Key Facts
- Report date: August 14, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and business updates.
- Company is classified as an 'Emerging Growth Company'.
Metagenomi, Inc. announced its financial results for the quarter ended March 31, 2024, and provided a corporate presentation update.
🚩 Red Flags
- None identified in the provided text; standard quarterly earnings disclosure.
📋 Key Facts
- Reported earnings/financial condition for the quarter ending March 31, 2024 (Item 2.02).
- Released May 2024 corporate presentation (Item 7.01).
- Company is classified as an 'Emerging Growth Company'.
- Filed on May 14, 2024.
Metagenomi, Inc. has mutually terminated its Strategic Collaboration and License Agreement with ModernaTX, Inc., effective April 26, 2024. As a result of the termination, Metagenomi regains full rights to its base editing and RNA-mediated integration systems (RIGS) but will no longer receive future payments from Moderna.
🚩 Red Flags
- Loss of significant strategic partner (Moderna).
- Cessation of future royalty/milestone payments from the Moderna collaboration.
- Termination of a material agreement can signal a shift in strategic direction or failure to meet specific milestones required by the partner.
📋 Key Facts
- Termination Date: April 26, 2024.
- The agreement with ModernaTX, Inc. was terminated in its entirety.
- Metagenomi regains full development and commercialization rights to its wholly-owned base editing and RNA-mediated integration systems (RIGS).
- Company will not receive any future payments from Moderna pursuant to the termination.
- Estimated cash and cash equivalents as of March 31, 2024: ~$327.4 million.
Metagenomi, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided additional business updates.
📋 Key Facts
- Report date: March 27, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is classified as an 'Emerging Growth Company'.
Metagenomi, Inc. filed an 8-K to amend and restate its Certificate of Incorporation and Bylaws in connection with the consummation of its Initial Public Offering (IPO). These changes are standard administrative updates required for transitioning from a private to a public entity.
🚩 Red Flags
- Elimination of stockholder's right to act by written consent (common in IPOs but reduces shareholder power).
📋 Key Facts
- Amended and Restated Certificate of Incorporation authorizes 500,000,000 shares of common stock.
- The company eliminated all references to previously existing series of preferred stock.
- Authorized 10,000,000 shares of undesignated preferred stock for future Board issuance.
- Amended and Restated Bylaws eliminate the ability of stockholders to take action by written consent in lieu of a meeting.
- New bylaws establish an advance notice procedure for stockholder proposals and director nominations.